FluoGuide proceeds to sixth dose level with FG001 in the ongoing clinical phase I/II trial following strong data from the concluded evening dosing
Copenhagen, Denmark, 17 August 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to report that FG001 was well tolerated, and light was detected in all patients, as anticipated, in the fifth cohort (16 mg) administered the evening before surgery. The Company will initiate the safety testing of the sixth dose level (24mg) in the ongoing clinical phase I/II trial evaluating safety and efficacy of FG001 in patients with aggressive brain cancer (high grade glioma) undergoing neurosurgery. The safety reporting is anticipated to be in Q3-2021, and the optimal dose selection and top-